# ARHGEF15

## Overview
ARHGEF15 is a gene that encodes the protein Rho guanine nucleotide exchange factor 15, which is a critical regulator of Rho GTPases. These proteins are involved in various cellular processes, including cytoskeletal organization, cell migration, and cell cycle progression. As a guanine nucleotide exchange factor (GEF), ARHGEF15 facilitates the activation of Rho proteins by promoting the exchange of GDP for GTP. The protein is predominantly active in the cytoplasm and plays a significant role in vascular development, particularly in the stabilization of blood vessels. It is primarily expressed in arterial endothelial cells and is upregulated by vascular endothelial growth factor A (VEGF-A), indicating its involvement in VEGF signaling pathways (Takase2012Genomewide). ARHGEF15 is also implicated in pathological conditions, such as pancreatic ductal adenocarcinoma, where its overexpression is associated with enhanced cancer cell motility and proliferation (Fukushima2016ARHGEF15).

## Function
ARHGEF15, also known as Rho guanine nucleotide exchange factor 15, is involved in the regulation of Rho GTPases, which are critical for various cellular processes such as cytoskeletal organization, cell migration, and cell cycle progression. It acts by facilitating the exchange of GDP for GTP on Rho proteins, thereby activating them. ARHGEF15 is primarily active in the cytoplasm and plays a significant role in vascular development, particularly in the stabilization of blood vessels. It is expressed predominantly in arterial endothelial cells and is upregulated by VEGF-A, indicating its role downstream of VEGF signaling (Takase2012Genomewide).

In endothelial cells, ARHGEF15 contributes to maintaining endothelial adhesions and is considered a positive regulator in angiogenic responses. Its expression is reduced in tumor-derived endothelial cells, suggesting a shift in endothelial cell behavior that may affect vascular stability and angiogenesis (HernándezGarcía2015Endothelial). The gene is also implicated in the development of endothelial cells during embryogenesis, with significant expression in human umbilical vein endothelial cells (HUVECs), where its knockdown reduces the ability for vascular network formation (Takase2012Genomewide). These functions highlight ARHGEF15's importance in both physiological and pathological angiogenesis.

## Clinical Significance
ARHGEF15, also known as Rho guanine nucleotide exchange factor 15, has been implicated in the progression of pancreatic ductal adenocarcinoma (PDAC), a highly aggressive form of cancer. Overexpression of ARHGEF15 in PDAC is associated with a poor prognosis, as it enhances the motility and proliferative activity of cancer cells. This overexpression leads to the activation of Rho-family proteins, such as RhoA, Cdc42, and Rac1, which are involved in cytoskeleton organization and cell motility, contributing to the aggressiveness of the cancer (Fukushima2016ARHGEF15).

Studies have shown that silencing ARHGEF15 in pancreatic cancer cell lines reduces the activity of these Rho signaling pathway molecules, resulting in decreased cell motility and viability. Conversely, overexpression of ARHGEF15 increases cell growth and motility, suggesting its role in cancer cell proliferation and migration (Fukushima2016ARHGEF15). The potential for ARHGEF15 as a therapeutic target is highlighted by the possibility of developing small molecule inhibitors to suppress its activity, which could have anti-cancer effects, including metastasis-inhibitory and antiproliferative outcomes (Fukushima2016ARHGEF15).


## References


[1. (Fukushima2016ARHGEF15) Hiroto Fukushima, Makiko Yasumoto, Sachiko Ogasawara, Jun Akiba, Yuhei Kitasato, Masamichi Nakayama, Yoshiki Naito, Yusuke Ishida, Yoshinobu Okabe, Masafumi Yasunaga, Hiroyuki Horiuchi, Etsuko Sakamoto, Hiraku Itadani, Shinji Mizuarai, Shinji Oie, and Hirohisa Yano. Arhgef15 overexpression worsens the prognosis in patients with pancreatic ductal adenocarcinoma through enhancing the motility and proliferative activity of the cancer cells. Molecular Cancer, May 2016. URL: http://dx.doi.org/10.1186/s12943-016-0516-4, doi:10.1186/s12943-016-0516-4. This article has 12 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1186/s12943-016-0516-4)

[2. (Takase2012Genomewide) Haruka Takase, Ken Matsumoto, Rie Yamadera, Yoshiaki Kubota, Ayaka Otsu, Rumiko Suzuki, Hiroyuki Ishitobi, Hiromi Mochizuki, Takahiro Kojima, Shingo Takano, Kazuhiko Uchida, Satoru Takahashi, and Masatsugu Ema. Genome-wide identification of endothelial cell–enriched genes in the mouse embryo. Blood, 120(4):914–923, July 2012. URL: http://dx.doi.org/10.1182/blood-2011-12-398156, doi:10.1182/blood-2011-12-398156. This article has 53 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1182/blood-2011-12-398156)

[3. (HernándezGarcía2015Endothelial) Ricardo Hernández-García, M. Luisa Iruela-Arispe, Guadalupe Reyes-Cruz, and José Vázquez-Prado. Endothelial rhogefs: a systematic analysis of their expression profiles in vegf-stimulated and tumor endothelial cells. Vascular Pharmacology, 74:60–72, November 2015. URL: http://dx.doi.org/10.1016/j.vph.2015.10.003, doi:10.1016/j.vph.2015.10.003. This article has 43 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.vph.2015.10.003)